Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial
No effective drug treatments are available for coronavirus disease 2019 (COVID-19). Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage, death, or long-term functional disability in survivors require clinical evaluation. We performed a parall...
- Autores:
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/14046
- Acceso en línea:
- https://doi.org/10.1038/s41392-020-00286-5
http://hdl.handle.net/20.500.12010/14046
- Palabra clave:
- Human umbilical cord-derived
Stem cell therapy
COVID-19
Patients
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
Clinical trial
- Rights
- License
- Abierto (Texto Completo)